TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02285543
Drug: TPF induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPF induction chemotherapy: 2 cycles; docetaxel(75mg/m\^2), cisplatin(75 mg/m\^2), 5-Fu(750 mg/m\^2/day) for 5 days; 16 days later, the 2nd cycle. 2 weeks later, surgery.~Surgery: radical resection and full neck dissection with reconstruction. Radiotherapy: 4-6 weeks after surgery, 1.8-2Gy/day, 5 days/week for 6 weeks, and totally 54-60Gy
Study: NCT00003884
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00004400
Drug: testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04017832
Drug: Placebo (oral semaglutide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet to be taken first thing in the morning
Study: NCT04017832
Drug: Placebo (sitagliptin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet to be taken 30 minutes after oral semaglutide
Study: NCT02203656
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo supplement
Study: NCT02930473
Drug: Psychopharmaceuticals (any drugs prescribed by the psychiatrist)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated only by psychopharmaceuticals prescribed by their psychiatrist.
Study: NCT00005046
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02203656
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone injection
Study: NCT04584736
Drug: Livalo, Ezetrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin+Ezetimibe Pitavastatin
Study: NCT02938286
Drug: AHES
Normalized name: STOMAHESIVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application at test region I-IV under occlusion for 15 minutes
Study: NCT04127513
Drug: Urea
Normalized name: Urea
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% urea moisturizing cream
Study: NCT02255318
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02344290
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet taken once daily, orally with or without food
Study: NCT00865917
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching appearance
Study: NCT02792114
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02792114
Drug: AP1903
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03005223
Drug: Co-administration of DWC20155/DWC20156
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03005223
Drug: DWC20163
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04450407
Drug: LY3209590
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT03061656
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1st HDCT
Study: NCT02548351
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04054973
Drug: Sapropterin Dihydrochloride
Normalized name: Sapropterin Dihydrochloride
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 800mg of Kuvan daily for 14 days
Study: NCT00110032
Drug: EF5
Normalized name: Hb 76(EF5), Met-thr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00927966
Drug: CP-751,871
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given intravenously on Day 1 of a 21-day cycle
Study: NCT04284930
Drug: OnQ pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: group 2: Surgeons receive instruction sheet with specific placement of catheter. All patients have two OnQ soaker catheters installed into abdominal donor site before donor closure.
Study: NCT02101931
Drug: Amino levulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The bladder cancer patients is required to swallow a chemical called Amino levulinic Acid, about 10mg/kg body weight. 5ml of blood and one urine samples will be taken before using Amino levulinic Acid. The patient must drink water then the urine will be collected after 4, 8 and 12 hours of taking ALA and the samples will be analyzed by photodynamic diagnostic procedure. ALA gets metabolized into certain types of porphyrins which selectively bind on to the tumor tissues (for a longer time than the normal tissues).
Study: NCT04092673
Drug: eFT226
Approvals — FDA: no, EMA: no, PMDA: no
Description: eFT226 is a novel small-molecule, investigational drug being developed by eFFECTOR Therapeutics as an anticancer therapy. eFT226 is a potent and selective inhibitor of eIF4A1-mediated translation and selectively regulates the translation of a subset of mRNAs based on sequence specific recognition motifs in their 5'-UTR. eIF4A1 inhibition by eFT226 downregulates expression of receptor tyrosine kinases and KRAS, leading to decreased signaling through the PI3K/AKT and MAPK pathways. Preclinical efficacy testing of eFT226 demonstrates activity across models of solid tumor cancers with amplifications in HER2, FGFR1/2 and mutations in KRAS (including breast, NSCLC and CRC).
Study: NCT01618474
Drug: XELOX
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oxaliplatin 130mg/m2, intravenous infusion, day 1; Capecitabine 1000mg/m2, oral administration, twice a day, day 1-14, 3 weeks a cycle for 8 consecutive cycles
Study: NCT04781361
Drug: Intravenous isotonic fluid - NaCl 131-154 mmol/L in 5% dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic group will be given fluids containing 131-154 mmol/L Sodium Chloride
Study: NCT02244164
Drug: Incretinomimetics
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04618601
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients randomized to the high-dose spironolactone group will receive oral spironolactone (≥100 mg) on top of standard of care treatment for acute heart failure immediately after randomization and in the afternoon of each subsequent day unless the serum potassium level is \>5 mmol/L. The exact dose will be determined based on a pre-specified algorithm provided.
Study: NCT03784040
Drug: OTSGC-A24
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OTSGC-A24 is administered as a subcutaneous (under the skin) injection. Nivolumab and ipilimumab are administered by intravenous (IV) infusion, meaning the drug is given through a catheter in a vein. A pump will be used to ensure the correct amount of medicine is given through the catheter. The nivolumab and ipilimumab infusions each take about 30 minutes. There will be a break of about 30 minutes in between the nivolumab and ipilimumab infusions (if given on the same day). OTSGC-A24 and nivolumab are administered every 2 weeks, while ipilimumab is administered every 6 weeks.
Study: NCT03128320
Drug: BAY1193397
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 1 mg BAY1193397 given in the fasted state
Study: NCT03128320
Drug: BAY1193397
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 5 mg BAY1193397 given in the fasted state
Study: NCT03128320
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of placebo given in the fasted state
Study: NCT04483492
Drug: Caffeine citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: diaphragm contractility after administration
Study: NCT02188472
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: 2 tablets should be taken twice daily
Study: NCT02089334
Drug: RX-0201
Approvals — FDA: no, EMA: no, PMDA: no
Description: RX-0201 will be administered in a dose up to 250mg/m\^2/day as a continuous infusion for a cycle of 21 days (14 days infused followed by 7 days off) for up to 8 cycles in Stage 1.~In Stage 2, RX-0201 will be administered the dose determined in Stage 1 as a continuous infusion for a cycle of 21 days (14 days infused followed by 7 days off) for up to 8 cycles.
Study: NCT00792376
Drug: etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: etoricoxib (ETO) group (n=28) treated with etoricoxib 120 mg/day orally for 7 days
Study: NCT00792376
Drug: diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: diclofenac (DIC) group (n=28) received diclofenac 150 mg/day/7 days orally.
Study: NCT01862939
Drug: DS-7309
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1, 2.5, 5, 10, 20 mg DS-7309 powder in bottle.
Study: NCT01862939
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo to match part 2 DS-7309
Study: NCT01188876
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally on a daily basis starting 7 days before the first dose of pralatrexate and continuing until 30 days after the last dose of pralatrexate.
Study: NCT03245385
Drug: Treatment with Halobetasol propionate 0.05% topical spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with topical halobetasol 0.05% spray applied twice daily for 14 days. Patients will be instructed not to rub over the affected area after application of spray. Each patient is expected to receive 28 doses. The maximum amount of test product applied per week will not exceed 50 g
Study: NCT00722501
Drug: ERB-257
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03140072
Drug: AZD9898
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Parts 1 and 2 of the study, each subject/patient will receive a single dose (one dose level) of AZD9898, under fasted conditions. Starting dose in part 1 (SAD in healthy subjects) is 3 mg, subsequent doses will be selected based on emerging data. In Part 3 of the study, each subject will receive one dose level of AZD9898, once daily, under fasted or fed conditions. Subjects participating in Part 3B (food effect cohort) will receive an additional administration of the same dose, on the last day to investigate the effects of food.
Study: NCT03140072
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Parts 1 and 2 of the study, each subject/patient will receive a single dose (one dose level) of matching placebo, under fasted conditions. In Part 3 of the study, each subject will receive one dose level of matching placebo, once daily, under fasted or fed conditions. Subjects participating in Part 3B (food effect cohort) will receive an additional administration of the same dose, on the last day to investigate the effects of food.
Study: NCT04417972
Drug: SHR7280
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment
Study: NCT04417972
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: blank control
Study: NCT02211963
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05303324
Drug: ALXN1840
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received ALXN1840 at Hour 0 on Day 1 of the dosing period.
Study: NCT00656487
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matched placebo
Study: NCT06646328
Drug: Heparin sodium
Normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-fractional heparin will be used in one arm with an initial dose of 500-1000 IU/hour with adaptation of the infusion to the patient and the clotting time.
Study: NCT02093325
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This will be a Phase III, randomized, double-blind, placebo-controlled clinical trial. Qualified subjects will be randomly assigned to receive either the test treatment or the placebo at 2:1 ratio. Once subjects are randomized, they will be treated with Arm A: Eltrombopag 50 mg/day (n=55) or Arm B: placebo (n=28) once a day for 7 days.
Study: NCT04000698
Drug: Preparative regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparative chemotherapy before allogeneic HSCT~* Fludarabin~* Cytarabine~* Venetoclax~* Daratumomab~* Vecanoid Condition~* treosulfan~* fludarabine~* thiophosphomide~* Venetoclax~* Plerixafor GVHD prophylaxis~* abatacept~* tocilizumab~* rituximab~* HSCT from the haploidentical donor, ex vivo depleted of alpha/beta T lymphocytes
Study: NCT05871398
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02985983
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered Placebo by subcutaneous (SC) injection until week 16. Administered Brodalumab by SC injection from week 17 until week 66.
Study: NCT03164473
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral tablets : 2 mg/kg/day for 24 months
Study: NCT03164473
Drug: Placebo-azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral tablets for 24 months
Study: NCT02559791
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo once monthly for 2 months
Study: NCT00882856
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT04599933
Drug: CSF-1
Normalized name: CSF-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop bilaterally twice daily for approximately 2 weeks.
Study: NCT04599933
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop bilaterally twice daily for approximately 2 weeks.
Study: NCT01424046
Drug: standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will continue with current mixed insulin treatment using NPH , or lente, and regular insulin .
Study: NCT01297088
Drug: BAY86-9596
Approvals — FDA: no, EMA: no, PMDA: no
Description: One single dose administration of a diagnostic agent
Study: NCT01652014
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV over 1 hour on Day -6; after pre-hydration
Study: NCT01021761
Drug: Bromfenac
Normalized name: Bromfenac
DrugBank: Bromfenac (DB00963)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery
Study: NCT01021761
Drug: nepafenac
Normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: drug to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery
Study: NCT00614120
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride placebo, capsules
Study: NCT00614120
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide placebo, s.c. (under the skin) injection
Study: NCT00003913
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01775358
Drug: ALRN-5281 0.05 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01775358
Drug: Placebo 0.015 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01775358
Drug: Placebo 0.15mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01670799
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This is a pilot (feasibility) trial to determine the availability, concentration and racemic mixture of a clinically indicated pain medication, ketorolac, in the peritoneal cavity and the subsequent effect on free floating ovarian cancer cells in patients after cytoreductive surgery for ovarian cancer.
Study: NCT01409772
Drug: Ethanol Lock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol Lock
Study: NCT00268333
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00268333
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01869699
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: acetaminophen 1 gram/100mLs intravenously administered over 15 minutes
Study: NCT01869699
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline placebo Normal saline 100 mLs intravenous, administered over 15 minutes
Study: NCT00136435
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction Phaese: Given intravenously on day 1 and day 2 CNS Therapy: Given intravenously on day 1 Intensification: Given day 1 of each cycle
Study: NCT00136435
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction: Given intravenously on day 3. CNS Therapy: Given intrathecally 4 times over two weeks Intensification: Given intrathecally every 18 weeks Continuation: Given intravenously weekly and intrathecally every 18 weeks
Study: NCT00136435
Drug: leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction: Given intravenously or orally 36 hours after methotrexate
Study: NCT00136435
Drug: hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Induction: Given intrathecally on days 15 and 29. Intensification: Given intrathecally every 18 weeks. Continuation: Given intrathecally every 18 weeks.
Study: NCT00136435
Drug: e. coli L-asparaginase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensification: Given in to the muscle weekly.
Study: NCT00623714
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two puffs, of placebo, will be administered to each patient at each prespecified time point. A total of five (5) doses of placebo will be administered during the single blind run-in phase. and matching placebo will be administered in a 3-day period during Periods 1 and 2. Dosing will be twice a day for 3 days, ending after the morning dose on the third day.
Study: NCT01542502
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily subcutaneous injection
Study: NCT01314482
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200mg bd for 3 days before surgery
Study: NCT02935894
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg ibuprofen given to inhibit cyclooxygenase metabolism
Study: NCT03824743
Drug: Lactate Ringer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients managed with Lactate Ringer and obstetric hemorrhage
Study: NCT03824743
Drug: Plasma-lyte
Normalized name: Plasma-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients managed with Plasma-Lyte and obstetric hemorrhage
Study: NCT01848132
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide: intravenous, 750 mg/m2, day 1
Study: NCT01848132
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adriamycin:intravenous, 50 mg/m2, day 1
Study: NCT01499251
Drug: Ancillary Study
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Macitentan dosed initially for 8-14 days prior to craniotomy, then treatment interrupted from time of craniotomy until 7 days before start of dose dense temozolomide therapy. dose-dense temozolomide 150 mg/m2 body surface area alternating 1 week on 1 week off.
Study: NCT00488969
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02284568
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02284568
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules
Study: NCT04336449
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - single intravenous infusion
Study: NCT03731559
Drug: DTG 50 mg OD with food
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dolutegravir 50 mg once daily with food plus 2NRTIs in HIV/TB co-infected patients receiving RIF based anti-TB therapy
Study: NCT03731559
Drug: DTG 50 mg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir 50 mg BID plus 2NRTIs in HIV/TB co-infected patients receiving RIF based anti-TB therapy.
Study: NCT03219359
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Days 1 and 2: Cyclophosphamide 2gm/m2/day x 2 days (total dose 4gm/m2) Day 3 until leukapheresis: G-CSF 10μg/kg/day to CD34+ \>20x104/ml then leukapheresis daily to collection goal
Study: NCT03219359
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Day -6 to -3: Cyclophosphamide 50 mg/kg/day (200 mg/kg total dose)
Study: NCT02644980
Drug: Maintenance of anesthesia
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: After the intubation, target controlled infusion(TCI) of etomidate or propofol is maintained,rocuronium 0.15mg/kg and sufentanil is given when needed. When the operation is over, the TCI is stopped.
Study: NCT00509756
Drug: FXR-450
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule, single oral doses from 10 mg to 450 mg
Study: NCT00509756
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule similar to active drug
Study: NCT00655733
Drug: HMPL-004
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMPL-004 1200 mg/d
Study: NCT00655733
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1200 mg/d
Study: NCT01701193
Drug: Physiologic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01867294
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01867294
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given topically
Study: NCT01867294
Drug: Therapeutic Hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given topically
Study: NCT01576276
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 administrations of ketorolac over course of study